Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 262

1.

Ken Fearon.

Skipworth RJ, Stephens NA, Johns N, Guttridge DC, Tisdale MJ, Baracos VE, Glass DJ.

Cell Metab. 2016 Dec 13;24(6):765-766. doi: 10.1016/j.cmet.2016.11.010. Epub 2016 Dec 13. No abstract available.

2.

In vitro assessment of the combined effect of eicosapentaenoic acid, green tea extract and curcumin C3 on protein loss in C2C12 myotubes.

Mirza KA, Luo M, Pereira S, Voss A, Das T, Tisdale MJ.

In Vitro Cell Dev Biol Anim. 2016 Sep;52(8):838-45. doi: 10.1007/s11626-016-0051-z. Epub 2016 May 18.

PMID:
27194344
3.

The Green Tea Polyphenol Epigallocatechin-3-Gallate (EGCg) Attenuates Skeletal Muscle Atrophy in a Rat Model of Sarcopenia.

Meador BM, Mirza KA, Tian M, Skelding MB, Reaves LA, Edens NK, Tisdale MJ, Pereira SL.

J Frailty Aging. 2015;4(4):209-15. doi: 10.14283/jfa.2015.58.

PMID:
27031020
4.

Functional identity of receptors for proteolysis-inducing factor on human and murine skeletal muscle.

Mirza KA, Tisdale MJ.

Br J Cancer. 2014 Aug 26;111(5):903-8. doi: 10.1038/bjc.2014.379. Epub 2014 Aug 7.

5.

Comparison of the anticatabolic effects of leucine and Ca-β-hydroxy-β-methylbutyrate in experimental models of cancer cachexia.

Mirza KA, Pereira SL, Voss AC, Tisdale MJ.

Nutrition. 2014 Jul-Aug;30(7-8):807-13. doi: 10.1016/j.nut.2013.11.012. Epub 2013 Dec 4.

PMID:
24984997
6.

Attenuation of muscle wasting in murine C2C 12 myotubes by epigallocatechin-3-gallate.

Mirza KA, Pereira SL, Edens NK, Tisdale MJ.

J Cachexia Sarcopenia Muscle. 2014 Dec;5(4):339-45. doi: 10.1007/s13539-014-0139-9. Epub 2014 Mar 20.

7.

Role of β-adrenergic receptors in the oral activity of zinc-α2-glycoprotein (ZAG).

Russell ST, Tisdale MJ.

Endocrinology. 2012 Oct;153(10):4696-704. Epub 2012 Aug 17.

PMID:
22903615
8.

Role of Ca2+ in proteolysis-inducing factor (PIF)-induced atrophy of skeletal muscle.

Mirza KA, Tisdale MJ.

Cell Signal. 2012 Nov;24(11):2118-22. doi: 10.1016/j.cellsig.2012.07.016. Epub 2012 Jul 20.

PMID:
22820507
9.

Role of β-adrenergic receptors in the anti-obesity and anti-diabetic effects of zinc-α2-glycoprotien (ZAG).

Russell ST, Tisdale MJ.

Biochim Biophys Acta. 2012 Apr;1821(4):590-9. doi: 10.1016/j.bbalip.2011.12.003. Epub 2011 Dec 23.

PMID:
22227600
10.

Decreased NADPH oxidase expression and antioxidant activity in cachectic skeletal muscle.

Sullivan-Gunn MJ, Campbell-O'Sullivan SP, Tisdale MJ, Lewandowski PA.

J Cachexia Sarcopenia Muscle. 2011 Sep;2(3):181-188. Epub 2011 Aug 11.

11.

Attenuation of muscle atrophy by an N-terminal peptide of the receptor for proteolysis-inducing factor (PIF).

Mirza KA, Wyke SM, Tisdale MJ.

Br J Cancer. 2011 Jun 28;105(1):83-8. doi: 10.1038/bjc.2011.216. Epub 2011 Jun 14.

12.

Studies on the anti-obesity activity of zinc-α2-glycoprotein in the rat.

Russell ST, Tisdale MJ.

Int J Obes (Lond). 2011 May;35(5):658-65. doi: 10.1038/ijo.2010.193. Epub 2010 Sep 21.

PMID:
20856251
13.

Reversing cachexia.

Tisdale MJ.

Cell. 2010 Aug 20;142(4):511-2. doi: 10.1016/j.cell.2010.08.004.

14.

Mechanism of attenuation of skeletal muscle atrophy by zinc-alpha2-glycoprotein.

Russell ST, Tisdale MJ.

Endocrinology. 2010 Oct;151(10):4696-704. doi: 10.1210/en.2010-0532. Epub 2010 Aug 11.

PMID:
20702573
15.

Studies on the antiobesity effect of zinc-α2-glycoprotein in the ob/ob mouse.

Russell ST, Tisdale MJ.

Int J Obes (Lond). 2011 Mar;35(3):345-54. doi: 10.1038/ijo.2010.150. Epub 2010 Aug 10.

PMID:
20697416
16.

Are tumoral factors responsible for host tissue wasting in cancer cachexia?

Tisdale MJ.

Future Oncol. 2010 Apr;6(4):503-13. doi: 10.2217/fon.10.20.

PMID:
20373865
17.

The role of zinc in the anti-tumour and anti-cachectic activity of D-myo-inositol 1,2,6-triphosphate.

Russell ST, Siren PM, Siren MJ, Tisdale MJ.

Br J Cancer. 2010 Mar 2;102(5):833-6. doi: 10.1038/sj.bjc.6605562. Epub 2010 Feb 9.

18.

Mechanism of activation of dsRNA-dependent protein kinase (PKR) in muscle atrophy.

Eley HL, Russell ST, Tisdale MJ.

Cell Signal. 2010 May;22(5):783-90. doi: 10.1016/j.cellsig.2010.01.002. Epub 2010 Jan 13.

PMID:
20074639
19.

Antidiabetic properties of zinc-alpha2-glycoprotein in ob/ob mice.

Russell ST, Tisdale MJ.

Endocrinology. 2010 Mar;151(3):948-57. doi: 10.1210/en.2009-0827. Epub 2009 Dec 23.

PMID:
20032055
20.

Cancer cachexia.

Tisdale MJ.

Curr Opin Gastroenterol. 2010 Mar;26(2):146-51. doi: 10.1097/MOG.0b013e3283347e77. Review.

PMID:
19918173
21.

Zinc-alpha2-glycoprotein in cachexia and obesity.

Tisdale MJ.

Curr Opin Support Palliat Care. 2009 Dec;3(4):288-93. doi: 10.1097/SPC.0b013e328331c897. Review.

PMID:
19823091
22.

Mechanism of attenuation of protein loss in murine C2C12 myotubes by D-myo-inositol 1,2,6-triphosphate.

Russell ST, Siren PM, Siren MJ, Tisdale MJ.

Exp Cell Res. 2010 Jan 15;316(2):286-95. doi: 10.1016/j.yexcr.2009.08.013. Epub 2009 Aug 28.

PMID:
19716818
23.

Mechanism of attenuation by beta-hydroxy-beta-methylbutyrate of muscle protein degradation induced by lipopolysaccharide.

Russell ST, Tisdale MJ.

Mol Cell Biochem. 2009 Oct;330(1-2):171-9. doi: 10.1007/s11010-009-0130-5. Epub 2009 Apr 30.

PMID:
19404720
24.

Mechanisms of cancer cachexia.

Tisdale MJ.

Physiol Rev. 2009 Apr;89(2):381-410. doi: 10.1152/physrev.00016.2008. Review.

25.

Attenuation of skeletal muscle atrophy in cancer cachexia by D-myo-inositol 1,2,6-triphosphate.

Russell ST, Siren PM, Siren MJ, Tisdale MJ.

Cancer Chemother Pharmacol. 2009 Aug;64(3):517-27. doi: 10.1007/s00280-008-0899-z. Epub 2008 Dec 27.

PMID:
19112551
26.

Catabolic mediators of cancer cachexia.

Tisdale MJ.

Curr Opin Support Palliat Care. 2008 Dec;2(4):256-61. Review.

PMID:
19069310
27.

Mechanism of induction of muscle protein loss by hyperglycaemia.

Russell ST, Rajani S, Dhadda RS, Tisdale MJ.

Exp Cell Res. 2009 Jan 1;315(1):16-25. doi: 10.1016/j.yexcr.2008.10.002. Epub 2008 Oct 17.

PMID:
18973755
28.

Attenuation of depression of muscle protein synthesis induced by lipopolysaccharide, tumor necrosis factor, and angiotensin II by beta-hydroxy-beta-methylbutyrate.

Eley HL, Russell ST, Tisdale MJ.

Am J Physiol Endocrinol Metab. 2008 Dec;295(6):E1409-16. doi: 10.1152/ajpendo.90530.2008. Epub 2008 Oct 14.

29.

Mechanism of attenuation of muscle protein degradation induced by tumor necrosis factor-alpha and angiotensin II by beta-hydroxy-beta-methylbutyrate.

Eley HL, Russell ST, Tisdale MJ.

Am J Physiol Endocrinol Metab. 2008 Dec;295(6):E1417-26. doi: 10.1152/ajpendo.90567.2008. Epub 2008 Oct 7.

30.

Downregulation of muscle protein degradation in sepsis by eicosapentaenoic acid (EPA).

Khal J, Tisdale MJ.

Biochem Biophys Res Commun. 2008 Oct 17;375(2):238-40. doi: 10.1016/j.bbrc.2008.08.004. Epub 2008 Aug 12.

PMID:
18703014
31.

Is there a common mechanism linking muscle wasting in various disease types?

Tisdale MJ.

Curr Opin Support Palliat Care. 2007 Dec;1(4):287-92. doi: 10.1097/SPC.0b013e3282f35238. Review.

PMID:
18685377
32.

Inhibition of activation of dsRNA-dependent protein kinase and tumour growth inhibition.

Eley HL, McDonald PS, Russell ST, Tisdale MJ.

Cancer Chemother Pharmacol. 2009 Mar;63(4):651-9. doi: 10.1007/s00280-008-0782-y. Epub 2008 Jun 14.

PMID:
18553083
33.

Re: Wieland BM, et al. Is there a human homologue to the murine proteolysis-inducing factor?

Tisdale MJ.

Clin Cancer Res. 2008 Apr 1;14(7):2245; author reply 2245-6. doi: 10.1158/1078-0432.CCR-07-4769. No abstract available.

34.

Role of the dsRNA-dependent protein kinase (PKR) in the attenuation of protein loss from muscle by insulin and insulin-like growth factor-I (IGF-I).

Eley HL, Russell ST, Tisdale MJ.

Mol Cell Biochem. 2008 Jun;313(1-2):63-9. doi: 10.1007/s11010-008-9742-4. Epub 2008 Mar 23.

PMID:
18360789
35.

Metabolic and morphological alterations induced by proteolysis-inducing factor from Walker tumour-bearing rats in C2C12 myotubes.

Yano CL, Ventrucci G, Field WN, Tisdale MJ, Gomes-Marcondes MC.

BMC Cancer. 2008 Jan 28;8:24. doi: 10.1186/1471-2407-8-24.

36.

Reply: Expression of the proteolysis-inducing factor core-peptide mRNA is upregulated in both tumour and adjacent normal tissue in gastrooesophageal malignancy.

Deans DA, Wigmore SJ, Gilmour H, Tisdale MJ, Fearon KC, Ross JA.

Br J Cancer. 2008 Jan 15;98(1):243. Epub 2007 Dec 18. No abstract available.

37.
38.
39.
40.

Effect of branched-chain amino acids on muscle atrophy in cancer cachexia.

Eley HL, Russell ST, Tisdale MJ.

Biochem J. 2007 Oct 1;407(1):113-20.

41.

Signaling pathways initiated by beta-hydroxy-beta-methylbutyrate to attenuate the depression of protein synthesis in skeletal muscle in response to cachectic stimuli.

Eley HL, Russell ST, Baxter JH, Mukerji P, Tisdale MJ.

Am J Physiol Endocrinol Metab. 2007 Oct;293(4):E923-31. Epub 2007 Jul 3.

42.

Role of reactive oxygen species in protein degradation in murine myotubes induced by proteolysis-inducing factor and angiotensin II.

Russell ST, Eley H, Tisdale MJ.

Cell Signal. 2007 Aug;19(8):1797-806. Epub 2007 Apr 19.

PMID:
17532611
43.

Attenuation of muscle atrophy in a murine model of cachexia by inhibition of the dsRNA-dependent protein kinase.

Eley HL, Russell ST, Tisdale MJ.

Br J Cancer. 2007 Apr 23;96(8):1216-22. Epub 2007 Mar 27.

44.

Mechanism of attenuation of angiotensin-II-induced protein degradation by insulin-like growth factor-I (IGF-I).

Russell ST, Eley H, Tisdale MJ.

Cell Signal. 2007 Jul;19(7):1583-95. Epub 2007 Feb 21.

PMID:
17376652
45.

Skeletal muscle atrophy, a link between depression of protein synthesis and increase in degradation.

Eley HL, Tisdale MJ.

J Biol Chem. 2007 Mar 9;282(10):7087-97. Epub 2007 Jan 9.

46.

Changes in nucleic acid and protein levels in atrophying skeletal muscle in cancer cachexia.

Bhogal AS, Lorite ML, Tisdale MJ.

Anticancer Res. 2006 Nov-Dec;26(6B):4149-54.

47.

Eicosapentaenoic acid containing nutritional supplements for the treatment of cancer cachexia.

Tisdale MJ.

Clin Nutr. 2007 Feb;26(1):161-2; author reply 163. Epub 2006 Oct 18. No abstract available.

PMID:
17055119
48.

Adipose atrophy in cancer cachexia: morphologic and molecular analysis of adipose tissue in tumour-bearing mice.

Bing C, Russell S, Becket E, Pope M, Tisdale MJ, Trayhurn P, Jenkins JR.

Br J Cancer. 2006 Oct 23;95(8):1028-37. Epub 2006 Oct 3.

49.

Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia.

Fearon KC, Barber MD, Moses AG, Ahmedzai SH, Taylor GS, Tisdale MJ, Murray GD.

J Clin Oncol. 2006 Jul 20;24(21):3401-7.

PMID:
16849754
50.

Clinical anticachexia treatments.

Tisdale MJ.

Nutr Clin Pract. 2006 Apr;21(2):168-74. Review.

PMID:
16556927

Supplemental Content

Loading ...
Support Center